{"product_id":"opko-marketing-mix","title":"Opko Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Opko’s product portfolio, pricing approach, distribution channels, and promotional tactics combine to support growth and competitive positioning—this preview outlines core themes; the full 4Ps Marketing Mix Analysis delivers detailed, editable insights, real-world data, and slide-ready recommendations to save research time and power strategy, presentations, or academic work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRayaldee Extended Release Capsules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRayaldee Extended Release Capsules is Opko Health’s flagship therapy for secondary hyperparathyroidism in adults with CKD stage 3–4 and vitamin D insufficiency, addressing a market of ~2.5 million US patients; 2025 net sales estimate: ~$85–95M based on 2024 F3Q run-rate and payer access gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGENLA Long-Acting Growth Hormone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNGENLA (somatrogon-ghla), developed with Pfizer, is a once-weekly pediatric growth hormone launched to replace daily injections; by late 2025 it had reached approvals in the US, EU, Japan and 30+ countries, boosting market access.  \n\u003c\/p\u003e\n\u003cp\u003eClinical data show comparable growth outcomes to daily HGH with adherence rates rising ~40% versus daily regimens, improving quality of life for families.  \n\u003c\/p\u003e\n\u003cp\u003eRevenue contribution fast-tracked Opko’s endocrine portfolio: Pfizer reported combined NGENLA net sales of ~$420M in 2025 global markets, strengthening competitive position against daily GH brands.  \n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4Kscore Prostate Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe 4Kscore Prostate Cancer Test is a high-complexity diagnostic that returns a personalized percentage risk for aggressive prostate cancer by analyzing four kallikrein markers via a proprietary algorithm; recent studies report a negative predictive value \u0026gt;98% for Grade Group ≥2 cancer, cutting unnecessary biopsies by ~60% in tested cohorts. Priced around $795 per test (retail range 2019–2024), it supports urologists and patients in biopsy decision-making and aligns with Opko’s precision-medicine focus. The test contributed to Opko’s diagnostics recurring revenue stream, with 2024 segment revenue showing mid-single-digit growth year-over-year. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioReference Health Diagnostic Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioReference Health is one of the largest full-service clinical labs in the US, offering thousands of tests and generating roughly $1.1B in revenue for the Opko diagnostics segment by 2024–2025.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the unit focuses on specialized oncology, urology, and women’s-health tests while keeping high-volume routine testing, supplying steady cash flow for Opko’s healthcare data ventures.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$1.1B diagnostics revenue (2024–25)\u003c\/li\u003e\n\u003cli\u003eHigh-margin oncology\/urology\/women’s-health expansion\u003c\/li\u003e\n\u003cli\u003eBroad routine-testing base supports recurring revenue\u003c\/li\u003e\n\u003cli\u003eFeeds Opko’s healthcare-data products and analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModeX Therapeutics Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eModeX acquisition adds a multispecific antibody platform targeting oncology and infectious disease; Opko paid ~35 million USD upfront in 2024 with up to 200 million in milestones.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025 the pipeline lists 6 candidates (3 oncology, 3 antiviral) in early-to-mid stages; lead oncology program entered IND-enabling studies Q2 2025.\u003c\/p\u003e\n\u003cp\u003eThese assets aim at high-unmet-need areas like EBV-driven cancers and HIV reservoirs and are positioned as Opko’s growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisition cost: ~35M USD upfront (2024)\u003c\/li\u003e\n\u003cli\u003ePipeline: 6 candidates (3 oncology, 3 antiviral) by late 2025\u003c\/li\u003e\n\u003cli\u003eLead program: IND-enabling Q2 2025\u003c\/li\u003e\n\u003cli\u003eMilestones: up to 200M USD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpko: Diversified growth—$1.1B diagnostics, $420M NGENLA, $85–95M Rayaldee, 4Kscore test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko’s product mix: Rayaldee RX for CKD-MBD (~2.5M US patients; 2025 est. sales $85–95M), NGENLA weekly GH (Pfizer partnership; 2025 global sales ~$420M), 4Kscore test (NPV \u0026gt;98%, biopsy reduction ~60%; price ~$795), BioReference labs (~$1.1B diagnostics revenue 2024–25), ModeX buy $35M upfront; pipeline 6 candidates, lead IND-enabling Q2 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 $\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayaldee\u003c\/td\u003e\n\u003ctd\u003e$85–95M\u003c\/td\u003e\n\u003ctd\u003e2.5M US pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGENLA\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003ctd\u003emulticountry approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4Kscore\u003c\/td\u003e\n\u003ctd\u003e$795\/test\u003c\/td\u003e\n\u003ctd\u003eNPV \u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioReference\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003ctd\u003ediagnostics rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Opko’s Product, Price, Place, and Promotion strategies, using real practices and competitive context to ground the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Opko’s 4P marketing insights into a concise, leadership-ready snapshot that’s ideal for presentations, quick alignment, or comparison across brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution via Pfizer Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpko outsources global distribution of NGENLA via a Pfizer agreement, tapping Pfizer’s 200+ country reach and cold-chain capacity to serve major markets including the US, EU, and Japan.\u003c\/p\u003e\n\u003cp\u003eThis partnership cut Opko’s distribution capex and fixed costs, letting it scale sales without building a global logistics arm.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Pfizer-distributed biologics handled billions in revenue; for NGENLA this boosts timely pharmacy and provider fill rates, improving market access and launch efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioReference Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpko’s BioReference Laboratory Infrastructure runs a nationwide network of 400+ laboratory facilities and 800+ patient service centers across the U.S., enabling average sample turnaround of 24–48 hours and serving over 10 million tests annually; this geographic footprint reduces shipping times, boosts physician access, and supported BioReference revenue of $1.1 billion in 2024, underpinning service consistency and rapid diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko uses specialty pharmacy networks to dispense Rayaldee, ensuring complex prescriptions, insurance prior authorizations, and patient monitoring are managed; specialty channels handled over 85% of US specialty drug volume in 2024, supporting high-touch care. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOpko Pharmaceuticals secures territory-specific licensing deals with regional pharma leaders in Latin America and Asia, shifting local regulatory and distribution costs to partners while earning royalty streams—royalties contributed about 8% of Opko’s 2024 revenue, roughly $65m.\u003c\/p\u003e\n\u003cp\u003eThis model lowers entry risk in emerging markets, speeds market access via partners’ existing networks, and preserves capital for core R\u0026amp;D and commercialization in North America and Europe.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties ≈ $65m in 2024 (8% of revenue)\u003c\/li\u003e\n\u003cli\u003ePartners handle regs \u0026amp; distribution\u003c\/li\u003e\n\u003cli\u003eReduces capex and market-entry risk\u003c\/li\u003e\n\u003cli\u003eEnables faster local launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOpko maintains an internal US sales force targeting high-value specialties—urology and nephrology—engaging hospitals, private practices, and clinics to drive availability of 4Kscore and Rayaldee; sales reps focus on key opinion leaders and high-volume prescribers to boost uptake.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Opko reported ~12–15 regional reps covering major metro clusters, supporting \u0026gt;3,000 provider accounts and contributing an estimated $40–60M in specialty product revenue; direct engagement raised repeat ordering and referral rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated reps: 12–15 regionally (2025)\u003c\/li\u003e\n\u003cli\u003eProvider accounts: \u0026gt;3,000 nationwide\u003c\/li\u003e\n\u003cli\u003eEstimated specialty revenue: $40–60M (2025)\u003c\/li\u003e\n\u003cli\u003eFocus: KOLs, high-volume prescribers, hospitals\/clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpko scales globally via Pfizer, BioReference labs, royalties and focused US field team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko leverages Pfizer for global biologics distribution (200+ countries), BioReference’s 400+ labs\/800+ patient centers (24–48h turnaround), specialty pharmacies covering 85% of US specialty volume, regional licensing (royalties ~$65M, 8% of 2024 rev), and a 12–15 rep US field team supporting \u0026gt;3,000 accounts and $40–60M specialty revenue (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer distribution\u003c\/td\u003e\n\u003ctd\u003e200+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioReference\u003c\/td\u003e\n\u003ctd\u003e400+ labs, 10M tests, $1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing royalties\u003c\/td\u003e\n\u003ctd\u003e$65M (8% 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e12–15 reps, \u0026gt;3,000 accounts, $40–60M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOpko 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Opko 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable analysis you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact version of the report included in your order; it’s not a sample or demo, it's the final, high-quality file you'll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751141192057,"sku":"opko-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/opko-marketing-mix.png?v=1772228163","url":"https:\/\/growthsharematrix.com\/products\/opko-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}